Zoliflodacin in Uncomplicated Gonorrhoea

PHASE3CompletedINTERVENTIONAL
Enrollment

1,011

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

August 30, 2023

Study Completion Date

September 18, 2023

Conditions
Gonorrhea
Interventions
DRUG

zoliflodacin

Dose: 3g, oral administration

DRUG

ceftriaxone

Dose: 500mg, Intra-Muscular (IM) administration

DRUG

azithromycin

Dose: 1g, oral administration

Trial Locations (17)

2000

Institute of Tropical Medicine, Antwerp

2001

Wits RHI, Johannesburg

3660

SAMRC Botha's Hill Clinical Research Site, Bothas Hill

4400

SAMRC Tongaat Clinical Research Site, Tongaat

7975

Masiphumelele Research Site, Cape Town

10120

Bangrak STI Center, Bangkok

10330

Institute of HIV Research and Innovation, Bangkok

10400

Silom Community Clinic, Bangkok

35233

Jefferson County Department of Health, Birmingham

46202

Bell Flower Clinic, Indianapolis

70112

Louisiana State University Health Sciences Center, New Orleans

94103

San Francisco Department Of Public Health City Clinic, San Francisco

98104

Public Health - Seattle & King County STD Clinic, Seattle

35294-0006

University of Alabama at Birmingham, Birmingham

1018 WT

Public Health Service (GGD) Amsterdam / STI Outpatient Clinic, Amsterdam

0470

Ndlovu Research Centre, Elandsdoorn

0152

Setshaba Research Centre, Soshanguve

All Listed Sponsors
lead

Global Antibiotics Research and Development Partnership

OTHER

NCT03959527 - Zoliflodacin in Uncomplicated Gonorrhoea | Biotech Hunter | Biotech Hunter